AKITA, by Finnadvance

Our distributor, MineBio Life Sciences Limited, will showcase our platform at the 12th Annual Conference of Drug Toxicology in Shanghai next week.

We are thrilled to announce our collaboration with Syngene International Limited, which has validated our AKITA platform for 2X faster Caco-2 assays, reducing the assay readiness time from 21 to just 12 days! This breakthrough promises significant savings in both time and costs for more efficient #preclinical drug testing. #drugdiscovery #pharma #caco2

Our research and development has been co-funded by the EU for the advancement of the highly scalable AKITA organ-on-chip platform. This initiative aims at de-risking preclinical drug testing by the development of predictive in vitro models 🔬 #organ-on-chip #microfluidics #preclinicaldrugtesting #drugscreening

🚀 New publication! 🚀 Thrilled to announce that our collaborative research with AstraZeneca has just been published! Our team has developed an iPSC-derived endothelial cell (iEC) model that provides a robust platform for studying venous malformations (VMs) and potentially other vascular diseases with genetic origins. This work underscores the pivotal role of iPSCs in advancing our understanding of vascular disorders and paves the way for personalized medicine. This advancement marks a significant step towards utilizing organ-on-chip technology for modeling and screening platforms, ultimately aiming to discover novel treatments for vascular diseases.

Simplify complex biological readouts with our high-fidelity impedance spectroscopy and TEER lid. We have made the most compact system for manual and automated use, not only with our platform but with all legacy transwell plates! No workstation or dedicated computer is required. Get your results in our web app AKITA Core on your phone/tablet/PC. And yes, what you see is the whole impedance system for 96, 384, and our plates.

Join us at the Immuno-Oncology Summit in London this week! We are present at our booth Nr. 12 and showcasing our platform enabling in vitro tumor vascularization for preclinical therapy testing! #immunooncology #cancerresearch #organoid

Bio-inks for vascular modeling! We combined tight #vascular barriers with #3D cell culture in a scalable manner. Glue4Life's customizable and biodegradable bio-ink was applied on the AKITA microfluidic plate to study vascular network formation. The endothelial sprouting could be further combined with tissues and organoids for drug compound testing and bio-ink evaluation in medium & high-throughput formats.

新規取り扱いのご案内 Finnadvance社（フィンランド）と代理店契約を締結しました。 同社が開発製造した生体内バリアを再構成するorgan-on-chipのAKITAプラットフォームをご提供します。薬物動態、血管外漏出モデル、抗がん剤など様々な分野に応用可能です。 https://lnkd.in/d7f9gggt Finnadvance社について Finnadvance社（フィンランド）は前臨床創薬研究や科学的研究を加速させるorgan-on-chipを開発しました。このプラットフォームは、血液脳関門、癌オルガノイド、炎症、薬物耐性などの様々な生物学的バリアのモデルに適しています。96ウェル及び384ウェルフォーマットで提供されるため、一般的な実験器具や自動化装置と互換性があります。Finnadvance社は、organ-on-chipをこれまでに無く簡便で身近なものにします。 #organonchip #創薬 #東京未来スタイル #Finnadvance

ボンジュール! ⛩️  Our AKITA microfluidic platform has reached Japan thanks to the support of our distributor Tokyo Future Style, Inc. Style! ⛩️ This new collaboration will provide broader Japanese accessibility for the in vitro modeling of vascularized tissues including tumors, blood-brain barrier, gut, and more. 🧪🧫💥 Tokyo Future Style, Inc. Style is a Japanese trading company engaging in the bioscience field. With more than fifteen years of experience in marketing research tools. they are dedicated to supporting researchers to provide novel and unique products from across the world by utilizing their network. Their activities aim to contribute to human well-being and a sustainable environment. We are excited to have them on board as our first distributor!

Happy to be at #adpd2024 presenting our organ-on-chip platform AKITA Plate and exploring new opportunities for collaboration. Me and Sebastien Mosser will be here for the whole week at AKITA, by Finnadvance booth #32 🥳